Eton Pharma (NASDAQ: ETON) CEO sells stock over two days

Rhea-AI Filing Summary

Eton Pharmaceuticals, Inc. (ETON) reported that President & CEO Sean Brynjelsen sold a total of 100,000 shares of common stock in four open-market transactions on August 19–20, 2026. The sales used weighted average prices of $62.65, $62.12, $61.11, and $60.17 per share, each executed in multiple trades within stated price ranges.

Insider Trade Summary

Net Seller: 100,000 shares

Net Sell 4 txns

Insider BRYNJELSEN SEAN

Role President & CEO

Sold 100,000 shs ($6.09M)

Type	Security	Shares	Price	Value
Sale	Common Stock F2, F3	47,307	$60.17	$2.85M
Sale	Common Stock F2, F4	36,373	$61.11	$2.22M
Sale	Common Stock F2, F5	7,342	$62.12	$456K
Sale	Common Stock F1, F2	8,978	$62.65	$562K

Holdings After Transaction: Common Stock — 961,194 shares (Direct)

Footnotes (5)

1. F1. The shares were sold in multiple trades at prices ranging from $62.50 to $63.41. The price above reflects the weighted average sales price.
2. F2. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
3. F3. The shares were sold in multiple trades at prices ranging from $59.59 to $60.59. The price above reflects the weighted average sales price.
4. F4. The shares were sold in multiple trades at prices ranging from $60.61 to $61.61. The price above reflects the weighted average sales price.
5. F5. The shares were sold in multiple trades at prices ranging from $61.63 to $62.52. The price above reflects the weighted average sales price.

Key Figures

Total shares sold: 100,000 shares Shares sold at $62.65: 8,978 shares Shares sold at $62.12: 7,342 shares +4 more

7 metrics

Total shares sold 100,000 shares Net shares sold by Sean Brynjelsen on 2026-08-19 and 2026-08-20

Shares sold at $62.65 8,978 shares Common Stock sale on 2026-08-19 at weighted average price $62.65

Shares sold at $62.12 7,342 shares Common Stock sale on 2026-08-20 at weighted average price $62.12

Shares sold at $61.11 36,373 shares Common Stock sale on 2026-08-20 at weighted average price $61.11

Shares sold at $60.17 47,307 shares Common Stock sale on 2026-08-20 at weighted average price $60.17

Price range for $62.65 sale $62.50–$63.41 Multiple trades on 2026-08-19; reported price is weighted average

Price range for $60.17 sale $59.59–$60.59 Multiple trades on 2026-08-20; reported price is weighted average

Key Terms

weighted average sales price, open market or private transaction, Securities and Exchange Commission staff

3 terms

weighted average sales price financial

"The price above reflects the weighted average sales price."

open market or private transaction financial

"Sale in open market or private transaction"

Securities and Exchange Commission staff regulatory

"provide upon request by the Securities and Exchange Commission staff"

FAQ

What insider transaction did ETON report for Sean Brynjelsen?

Eton Pharmaceuticals (ETON) reported that President & CEO Sean Brynjelsen sold 100,000 shares of common stock in four open-market transactions on August 19–20, 2026, at various weighted average prices disclosed in the Form 4.

How many ETON shares did the CEO sell and on which dates?

Sean Brynjelsen sold a total of 100,000 ETON shares of common stock across four transactions on August 19, 2026 and August 20, 2026, as reported in the Form 4 insider filing.

At what prices were Sean Brynjelsen’s ETON shares sold?

The reported weighted average prices were $62.65, $62.12, $61.11, and $60.17 per share. Footnotes state each price is a weighted average sales price for multiple trades within specified intraday price ranges.

How many ETON shares were sold in each of Sean Brynjelsen’s transactions?

The reported sales were 8,978 shares at $62.65, 7,342 shares at $62.12, 36,373 shares at $61.11, and 47,307 shares at $60.17, each representing a weighted average price for multiple trades.

Were Sean Brynjelsen’s ETON share sales under a Rule 10b5-1 plan?

The Form 4 indicates the Rule 10b5-1 checkbox was not marked as affirmatively adopted for these transactions, and the footnotes do not describe the sales as being made under a Rule 10b5-1 trading plan.

How were the ETON sale price ranges described for these insider trades?

Footnotes state the shares on August 19, 2026 were sold between $62.50 and $63.41, and the August 20, 2026 trades were sold in ranges of $59.59–$60.59, $60.61–$61.61, and $61.63–$62.52, with each reported price being a weighted average.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/20/2026 - 06:26 PM Accepted by SEC EDGAR 08/20/2026 - 06:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BRYNJELSEN SEAN

(Last) (First) (Middle)

C/O ETON PHARMACEUTICALS, INC.

21925 W. FIELD PARKWAY, SUITE 235

(Street)

DEERPARK ILLINOIS 60010-7208

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Eton Pharmaceuticals, Inc. [ ETON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2026		S		8,978	D	$62.65(1)(2)	1,052,216	D
Common Stock	08/20/2026		S		47,307	D	$60.17(2)(3)	1,004,909	D
Common Stock	08/20/2026		S		36,373	D	$61.11(2)(4)	968,536	D
Common Stock	08/20/2026		S		7,342	D	$62.12(2)(5)	961,194	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold in multiple trades at prices ranging from $62.50 to $63.41. The price above reflects the weighted average sales price.

2. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. The shares were sold in multiple trades at prices ranging from $59.59 to $60.59. The price above reflects the weighted average sales price.

4. The shares were sold in multiple trades at prices ranging from $60.61 to $61.61. The price above reflects the weighted average sales price.

5. The shares were sold in multiple trades at prices ranging from $61.63 to $62.52. The price above reflects the weighted average sales price.

	/s/ Judith Matthews	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)